Adverse Reactions of Antibody-Therapy for Primary Cutaneous Lymphomas: Rituximab, Brentuximab Vedotin, Alemtuzumab, and Mogamulizumab.

Details

Serval ID
serval:BIB_CF3AB1580107
Type
Article: article from journal or magazin.
Collection
Publications
Title
Adverse Reactions of Antibody-Therapy for Primary Cutaneous Lymphomas: Rituximab, Brentuximab Vedotin, Alemtuzumab, and Mogamulizumab.
Journal
Current problems in dermatology
Author(s)
Saulite I, Guenova E, Hoetzenecker W
Publication state
Published
Issued date
2018
Language
english
Pubmed
Create date
27/08/2020 13:59
Last modification date
01/09/2020 5:26
Usage data